Phase 2a Study to Evaluate the Safety, Pharmacokinetics, and Pharmacodynamics of Repeated Administrations Over 4 Weeks of the Hepcidin Antagonist PRS-080#022-DP in Anemic Chronic Kidney Disease Patients Undergoing Hemodialysis

Status: Completed

Phase of Trial: Phase II

Latest Information Update: 03 Oct 2021

Price : $35 ^*

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs PRS 080 (Primary)
Indications Iron deficiency anaemia
Focus Adverse reactions
Sponsors Pieris Pharmaceuticals

Most Recent Events

01 Aug 2019 Results presented in the Pieris Pharmaceuticals media release.
06 Jun 2019 This trial has been completed in Czech Republic , according to European Clinical Trials Datab
10 May 2019 According to a Pieris Pharmaceuticals media release, the company will present data from this trial at the 24th European Hematology Association Congress on June 16, 2019.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com

Welcome to AdisInsight